Atypical fibroxanthoma and pleomorphic dermal sarcoma: Is superficial infiltration in subcutaneous tissue acceptable in AFX?

Publication date

2022-06

Authors

van Midden, Dominique
Flucke, Uta EISNI 0000000012486985
Amir, Avital L.
Bonenkamp, Johannes J
Lubeek, Satish F K
Blokx, WillekeORCID 0000-0002-4647-8830

Editors

Advisors

Supervisors

Document Type

Article

Collections

Open Access logo

License

cc_by

Abstract

BACKGROUND: Atypical fibroxanthoma (AFX) and pleomorphic dermal sarcoma (PDS) are rare cutaneous neoplasms forming a spectrum. Case reports with recurrences and metastasis have been published despite the current view that AFX is benign. The aim of this study was to identify clinical and histopathological features that predict tumor recurrence. METHODS: A retrospective review of AFX and PDS cases was performed. Clinical characteristics were obtained from patient records. RESULTS: A total of 29 AFX and 23 PDS cases were identified. Review led to re-classification of 12 cases (18%). In 14/50 (26.9%) cases a recurrence occurred. Recurrences were significantly more likely to occur when the tumor showed any infiltration in the subcutaneous fat (100% vs 43.2%, p = 0.000) or when the tumor diameter exceeded 2 cm (46.2% vs 16.2%, p = 0.030). CONCLUSIONS: This study shows that histopathological distinction between AFX and PDS remains difficult with reclassification in 12 out of 52 (18%) cases upon review. All AFX cases solely confined to the dermis behaved benign. We therefore advocate to classify all cases with any form of subcutaneous extension as PDS, and only lesions without as AFX. This contrasts with the current general opinion in which superficial subcutaneous invasion is still accepted in AFX.

Keywords

Atypical fibroxanthoma, Pleomorphic dermal sarcoma, Prognosis, Recurrence, Pathology and Forensic Medicine, Journal Article

Citation

van Midden, D, Flucke, U E, Amir, A L, Bonenkamp, J J, Lubeek, S F K & Blokx, W A M 2022, 'Atypical fibroxanthoma and pleomorphic dermal sarcoma : Is superficial infiltration in subcutaneous tissue acceptable in AFX?', Annals of Diagnostic Pathology, vol. 58, 151915, pp. 1-7. https://doi.org/10.1016/j.anndiagpath.2022.151915